Medical personnel show a vial containing the antiviral Remdesivir in a hospital in Essen, Germany.
SASCHA STEINBACH / EFE
NEW YORK – The United States Food and Drug Administration (FDA) granted final approval on Thursday as the first treatment against COVID-19 to the antiviral Remdesivir, to date the only one with authorization from the regulator to treat the disease.
In May the antiviral of Gilead Sciences received emergency authorization, a formula to allow use during the pandemic of the treatment still in its experimental stage, and now the FDA granted final approval for cases of COVID-19 patients hospitalized.
Remdesivir has allowed shorter recovery periods in some severe cases of coronavirus, although the World Health Organization (WHO) recently considered, after analyzing provisional data, that the antiviral, as well as others that have been administered to COVID-19 patients, has an almost negligible impact on reducing mortality.
Fauci endorses the antiviral
America’s leading epidemiologist, Dr. Anthony Fauci, has defended the use of Remdesivir, which is being administered to patients in the United States and with which President Donald Trump was treated during his convalescence at the beginning of the month.
With the authorization received, Remdesivir becomes the only treatment authorized in the United States for COVID-19, which has infected more than 41 million people around the world, although there are others that already have emergency authorization such as the use of plasma.
“It is incredible that in less than a year since the first reports of infected by the disease known as COVID-19 in the United States, we have a treatment that is available to all patients who need it,” said the CEO of Gilead, Daniel O’Day.
The pharmaceutical company expects to manufacture more than two million doses of the treatment this year, which is administered intravenously, and multiply that production capacity during 2021.
To do this, the company, which specializes in cancer or HIV treatments, has a network of suppliers and manufacturers around the world.
At the beginning of his treatment for coronavirus, President Donald Trump received intravenous doses of the drug, according to his medical team.
“Last night she received her first dose of intravenous Remdesivir. Our plan is to continue with a five-day treatment of remdesivir, ”Dr. Brian Garibaldi, one of the doctors on the team who treated Trump at the Walter Reed National Military Medical Center, told the media on October 4. .